Strategies for development of universal vaccines against meningococcal serogroup B disease: The most promising options and the challenges evaluating them

Human Vaccines

Volumn 3, Issue 6, 2007, Pages 290-294

  Holst, Johan ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Bacterial genomics; Cross reactive protection; Molecular epidemiology; Neisseria meningitidis; Pan genomic evaluation; Universal meningococcal vaccines

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; LIPOPOLYSACCHARIDE; MENINGOCOCCUS VACCINE; N PROPRIONYLATED B CAPSULAR POLYSACCHARIDE; OUTER MEMBRANE VESICLE; PORIN A; SIALIC ACID; TETANUS TOXOID; TRANSFERRIN BINDING PROTEIN A; TRANSFERRIN BINDING PROTEIN B; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIMICROBIAL ACTIVITY; BACTERIAL MEMBRANE; BACTERIAL STRAIN; CROSS REACTION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; MENINGOCOCCOSIS; NEISSERIA LACTAMICA; NEISSERIA MENINGITIDIS; NONHUMAN; NOTE;

EID: 37649010082     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4513     Document Type: Note

References (42)

1. st century. In: Kappy MS, Accurso FJ, Gilbert-Barness E, Barness LA, eds. Advances in Pediatrics. St. Louis, Missouri, USA: Mosby, Inc., 2005:129-62.
2. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plorkin SA, Offit PA, Orenstein WA, eds. Vaccines. 5th ed.
3. Maiden MCJ, Caugant DA. The population biology of Neisseria meningitidis: Implications for meningococcal disease, epidemiology and control. In: Frosch M, Maiden MJC, eds. Handbook of Meningococcal Disease. Weinheim, Germany: Wiley-VCH, 2006:17-35.
4. Anonymous: Control of epidemic meningococcal disease. WHO practical guidelines. 2nd ed. World Health Organization 1998.
5. Pollard AJ. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23:S274-9.
6. Sparling PF. A plethora of host factors that determine the outcome of meningococcal infection. Am J Med 2002; 112:72-4.
7. Jodár L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 2002; 359:1499-508.
8. Holst J, Aaberge IS, Oster P, Lennon D, Martin D, O'Hallahan J. A 'tailor made' vaccine mailed as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurveillance Weekly 2003; 7:030724, (http://www.eurosurveillance.org/ew/2003/030724.asp#5).
9. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
10. Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998; 177:497-500.
11. Oster P, O'Hallahan J, Aaberge I, Timan S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007; 25:3075-9.
12. Cartwright K, Noah N, Peltola H. Meningococcal disease in Europe: Epidemiology, mortality and prevention with conjugate vaccines: Report of a European advisory board meeting. Vienna, Austria, 6-8 October 2000. Vaccine 2001; 19:4347-56.
13. Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: A success story. Vaccine 2001; 20:S58-67.
14. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, Cieslak P, Shutt KA, Popovic T, Schuchat A, Harrison LH, Reingold AL. The changing epidemiology of meningococcal disease in United States, 1992-1996. J Infect Dis 1999; 180:1894-901.
15. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, Berman SL, Lowenthal JP. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972; 126:514-21.
16. Finne J, Leinonen M, Mäkela PH. Antigenic similarities between brain components and bacteria causing meningitis: Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7.
17. Jennings HJ, Roy G, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986; 137:1708-13.
18. Bruge J, Bouveret-Le Cam N, Danve B, Rougon G, Schulz D. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine 2004; 22:1087-96.
19. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, McHugh YE, Moe GR. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998; 160:5028-36.
20. Moe GR, Dave A, Granoff DM. Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect Immune 2005; 73:2123-8.
21. Holst J, Feiring B, Naess LM, Norheim G, Kristiansen P, Høiby EA, Bryn K, Oster P, Costantino P, Taha MK, Alonso JM, Caugant DA, Wedege E, Aaberge IS, Rappuoli R, Rosenqvist E. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005; 23:2202-5.
22. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, Nøkleby H, Rosenqvist E, Sierra G, Campa C, Sotolongo F, Vega J, Garcia J, Herrera P, Poolman JT, Perkins BA. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA 1999; 281:1520-7.
23. Boutriau D, Poolman J, Borrow R, Findlow J, Domingo JD, Puig-Barbera J, Baldó JM, Planelles V, Jubert A, Colomer J, Gil A, Levie K, Kervyn AD, Weynants V, Dominguez F, Barberá R, Sotolongo F. Immunogenicity and safety of three doses of a bivalent (B:4: p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007; 14:65-73.
24. Sandbu S, Feiring B, Oster P, Heiland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nekleby H, Rosenqvist E. Immunogenicity and safety of a combination of two Serogroup B meningococcal OMV vaccines. Clin Vaccine Immunol 2007; In Press.
25. Moe GR, Zuno-Mitchell P, Hammon SN, Granoff DM. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 2002; 70:6021-31.
26. van der Ley P, Poolman JT. Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein. Infect Immun 1992; 60:3156-61.
27. Ciaassen I, Meylis J, van der Ley P, Peeters C, Brons H, Robert J, Borsboom D, van der Ark A, van Straaten I, Roholl P, Kuipers B, Poolman J. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 1996; 14:1001-8.
28. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007; 25:2491-6.
29. Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N, Richmond P, Poolman J. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17:2612-9.
30. Gorringe A, Halliwell D, Matheson M, Reddin K, Finney M, Hudson M. The development of a meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Vaccine 2005; 23:2210-3.
31. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 2003; 302:602.
32. Giannelli V, Fontana MR, Giuliani MM, Guangcai D, Rappuoli R, Pizza M. A universal vaccine for serogroup B meningococcus. PNAS 2006; 103:1034-9.
33. Koeberling O, Welsch JA, Granoff DM. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine 2007; 25:1912-20.
34. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A, et al. Phase 1 first-in human studies of reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 2006; 25:450-7.
35. Rokbi B, Mignon M, Maitre-Wilmotte G, Lissolo L, Danve B, Caugant DA, Quentin-Miller MJ. Evaluation of recombinant transferring-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immune 1997; 65:55-63.
36. Wright JC, Plested JS, Moxon ER. Genetics, structure and function of lipopolysaccharide. In: Frosch M, Maiden MJC, eds. Handbook of Meningococcal Disease. Weinheim, Germany: Wiley-VCH, 2006:163-79.
37. Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003; 21:734-7.
38. Borrow R, Miller E. Surrogates of protection. In: Frosch M, Maiden MC. eds. Handbook of Meningococcal Disease. Weinheim, Germany: Wiley-VCH, 2006:323-41.
39. Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkönen A, Jonsson AB. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 2005; 23:2214-7.
40. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. Prevalence of factor H-binding protein Variants and NadA among meningococcal group B isolates from the United States: Implications for the development of a multicomponent group B vaccine. J Infect Dis 2007; 195:1472-9.
41. Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: The pneumococcal challenge. Vaccine 2007; 25:2963-73.
42. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM. Whole-genome random sequencing and assembly of Haemophilus influenzae. Science 1995; 269:496-512.